$0.05
−24.03%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.05
From 52W high−100.00%
Volume5.72M
Market cap$474530.77
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataNov 4, 2026
Open
$0.05
From 52W high
−100.00%
Volume
5.72M
Market cap
$474530.77
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.6x
P/E (TTM)
—
RSI (14)
15.0
MomentumView details →
1D Return
−24.03%
YTD Return
−100.00%
SummaryUpdated Jun 1, 2026
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) is a clinical-stage specialty biopharmaceutical company founded in 2019 and headquartered in San Diego, California. The company went public in March 2022 and operates as a subsidiary of Corvus Capital Limited. Conduit focuses on developing treatments for unmet medical needs in autoimmune diseases and male reproductive health, with a pipeline centered around two main drug candidates targeting conditions such as Hashimoto's thyroiditis and idiopathic male infertility.
Similar companies
Latest newsMore news →
CDT Equity entered into an evaluation agreement with Manoira Corporation to assess whether CDT’s AZD1656 assets, including proprietary cocrystal derivatives, and AZD5904 could enhance Manoira’s forthcoming animal health products.8d agoEQUITY BANCSHARES INC announced that its board fixed October 30, 2026, as the record date for a two-for-one subdivision of its equity shares, reducing face value from Rs. 10 to Rs. 5 per share.19d ago